Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.

Related Keywords

Matthew Galsky ,Danielle Ellis ,Bristol Myers Squibb ,European Society For Medical Oncology ,Tisch Cancer Center At Mount Sinai ,Tisch Cancer Institute ,Ono Pharmaceutical Company Ltd ,Mount Sinai ,New England Journal ,European Society ,Bladder Cancer ,Tisch Cancer Center ,Ono Pharmaceutical Company ,Bladder ,Dancer ,Chemotherapy ,Immunotherapy ,Children ,Cisplatin ,Clinical Trial ,Gemcitabine ,Geriatrics ,Health Care ,Hospital ,Medicine ,Ncology ,Surgery ,